MacroGenics (MGNX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Voting matters and shareholder proposals
Election of three Class I directors to serve until the 2029 Annual Meeting or until successors are appointed.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve executive compensation as disclosed in the proxy materials.
Approval of an amendment to the 2023 Equity Incentive Plan.
Board of directors and corporate governance
Board recommends a vote in favor of all proposals presented at the annual meeting.
Three nominees for Class I director positions are Scott Koenig, Federica O'Brien, and Eric Risser.
Audit committee and external auditor matters
Audit Committee selected Ernst & Young LLP as the independent auditor for the next fiscal year.
Shareholders are asked to ratify this selection at the annual meeting.
Latest events from MacroGenics
- Advancing a diverse oncology pipeline with strong financials and key partnerships.MGNX
Corporate presentation - CDMO sale and milestone gains drove profitability and a strong cash runway through 2028.MGNX
Q2 2026 - Advancing innovative antibody-based cancer therapies with strong financial backing and key 2026 milestones.MGNX
Corporate presentation - Major cash infusions and pipeline advances position the company for key value milestones.MGNX
Stifel 2026 Targeted Oncology Virtual Forum - Revenue up 58%, net loss narrowed, and divestiture plus royalty deal extend cash runway to 2028.MGNX
Q1 2026 - Shareholders are asked to approve an increase in equity awards to support talent retention and alignment.MGNX
Proxy filing - Board recommends voting for all proposals, including director elections and equity plan amendment.MGNX
Proxy filing - Key ADC and checkpoint programs advance toward major 2026 milestones, backed by strong partnerships.MGNX
Barclays 28th Annual Global Healthcare Conference - Vobra duo showed strong efficacy and improved safety in mCRPC, with mature data due in 2025.MGNX
Study Update